ACM
LXEO icon

Altium Capital Management’s Lexeo Therapeutics LXEO Stock Holding History

Altium Capital Management’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-405,000
Closed -$2.66M – 52
2024
Q4 		$2.66M Buy
+405,000
New +$3.19M 0.76% 43

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Altium Capital Management's LXEO Position: Q1 2025 in Review

Altium Capital Management sold out of Lexeo Therapeutics (LXEO) in Q1 2025, closing a stake of 405,000 shares — an estimated $2.66M sold.

Altium Capital Management first reported a position in LXEO in Q4 2024 and held it in 1 quarter. The position peaked at $2.66M in Q4 2024. 88 funds tracked by Wall St. Rank hold LXEO as of Q1 2025.

  • Altium Capital Management reported no remaining Lexeo Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Altium Capital Management sold 405,000 Lexeo Therapeutics shares in Q1 2025, an estimated $2.66M.
  • Altium Capital Management first reported a position in Lexeo Therapeutics in Q4 2024 and held it in 1 quarter.
  • Altium Capital Management's Lexeo Therapeutics position peaked at $2.66M in Q4 2024.
  • 88 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.